Medical - Instruments & Supplies
Build Your Comparison
Side-by-side financial analysisStock Comparison
NYXH vs AVAV vs JPM vs BAC vs KTOS
Revenue, margins, valuation, and 5-year total return — side by side.
Aerospace & Defense
Banks - Diversified
Banks - Diversified
Aerospace & Defense
NYXH vs AVAV vs JPM vs BAC vs KTOS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Instruments & Supplies | Aerospace & Defense | Banks - Diversified | Banks - Diversified | Aerospace & Defense |
| Market Cap | $52M | $8.52B | $896.00B | $422.78B | $10.83B |
| Revenue (TTM) | $16M | $1.61B | $280.33B | $191.57B | $1.42B |
| Net Income (TTM) | $-86M | $-224M | $57.05B | $30.51B | $29M |
| Gross Margin | 48.3% | 21.8% | 60.0% | 56.1% | 18.3% |
| Operating Margin | -5.3% | -8.3% | 25.9% | 19.7% | 1.8% |
| Forward P/E | — | 59.2x | 14.4x | 12.6x | 75.9x |
| Total Debt | $42M | $64M | $942.38B | $365.90B | $180M |
| Cash & Equiv. | $30M | $41M | $343.34B | $231.84B | $561M |
NYXH vs AVAV vs JPM vs BAC vs KTOS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Apr 21 | Jun 26 | Return |
|---|---|---|---|
| Nyxoah S.A. (NYXH) | 100 | 5.8 | -94.2% |
| AeroVironment, Inc. (AVAV) | 100 | 154.6 | +54.6% |
| JPMorgan Chase & Co. (JPM) | 100 | 208.5 | +108.5% |
| Bank of America Cor… (BAC) | 100 | 138.2 | +38.2% |
| Kratos Defense & Se… (KTOS) | 100 | 216.0 | +116.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NYXH vs AVAV vs JPM vs BAC vs KTOS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
NYXH is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 121.6%, EPS growth -30.9%, 3Y rev CAGR 48.1%
- 121.6% revenue growth vs BAC's -0.5%
AVAV is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 1.90, Low D/E 7.3%, current ratio 3.52x
JPM carries the broadest edge in this set and is the clearest fit for valuation efficiency and bank quality.
- PEG 0.81 vs BAC's 0.82
- NIM 2.2% vs BAC's 1.8%
- Lower P/E (14.4x vs 75.9x)
- 20.4% margin vs NYXH's -5.3%
BAC ranks third and is worth considering specifically for income & stability and defensive.
- Dividend streak 12 yrs, beta 0.86, yield 2.3%
- Beta 0.86, yield 2.3%, current ratio 0.42x
- Beta 0.86 vs KTOS's 2.18
KTOS is the clearest fit if your priority is long-term compounding.
- 13.5% 10Y total return vs JPM's 465.8%
- +40.0% vs NYXH's -81.6%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 121.6% revenue growth vs BAC's -0.5% | |
| Value | Lower P/E (14.4x vs 75.9x) | |
| Quality / Margins | 20.4% margin vs NYXH's -5.3% | |
| Stability / Safety | Beta 0.86 vs KTOS's 2.18 | |
| Dividends | 1.9% yield, 15-year raise streak, vs BAC's 2.3%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +40.0% vs NYXH's -81.6% | |
| Efficiency (ROA) | 1.3% ROA vs NYXH's -80.8%, ROIC 4.5% vs -76.4% |
NYXH vs AVAV vs JPM vs BAC vs KTOS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
NYXH vs AVAV vs JPM vs BAC vs KTOS — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
JPM leads in 2 of 6 categories
BAC leads 2 • KTOS leads 1 • NYXH leads 0 • AVAV leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
JPM leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
JPM is the larger business by revenue, generating $280.3B annually — 17179.4x NYXH's $16M. JPM is the more profitable business, keeping 20.4% of every revenue dollar as net income compared to NYXH's -5.3%. On growth, NYXH holds the edge at +5.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $16M | $1.6B | $280.3B | $191.6B | $1.4B |
| EBITDAEarnings before interest/tax | -$81M | $82M | $81.4B | $40.0B | $72M |
| Net IncomeAfter-tax profit | -$86M | -$224M | $57.0B | $30.5B | $29M |
| Free Cash FlowCash after capex | -$73M | -$183M | $100.9B | $12.6B | -$134M |
| Gross MarginGross profit ÷ Revenue | +48.3% | +21.8% | +60.0% | +56.1% | +18.3% |
| Operating MarginEBIT ÷ Revenue | -5.3% | -8.3% | +25.9% | +19.7% | +1.8% |
| Net MarginNet income ÷ Revenue | -5.3% | -13.9% | +20.4% | +15.9% | +2.1% |
| FCF MarginFCF ÷ Revenue | -4.5% | -11.3% | +36.0% | +6.6% | -9.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +5.9% | +143.4% | — | — | +22.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +38.3% | -51.5% | +16.0% | +18.3% | +133.3% |
Valuation Metrics
BAC leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 14.7x trailing earnings, BAC trades at a 97% valuation discount to KTOS's 444.2x P/E. Adjusting for growth (PEG ratio), JPM offers better value at 0.90x vs BAC's 0.95x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $52M | $8.5B | $896.0B | $422.8B | $10.8B |
| Enterprise ValueMkt cap + debt − cash | $66M | $8.5B | $1.50T | $556.8B | $10.4B |
| Trailing P/EPrice ÷ TTM EPS | -0.51x | 110.05x | 16.00x | 14.66x | 444.23x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 59.24x | 14.40x | 12.56x | 75.89x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 0.90x | 0.95x | — |
| EV / EBITDAEnterprise value multiple | — | 104.43x | 18.36x | 13.92x | 120.10x |
| Price / SalesMarket cap ÷ Revenue | 4.48x | 10.38x | 3.20x | 2.21x | 8.04x |
| Price / BookPrice ÷ Book value/share | 0.93x | 5.42x | 2.47x | 1.39x | 5.01x |
| Price / FCFMarket cap ÷ FCF | — | — | 8.88x | 33.52x | — |
Profitability & Efficiency
JPM leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
JPM delivers a 15.9% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $-164 for NYXH. AVAV carries lower financial leverage with a 0.07x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), BAC scores 7/9 vs NYXH's 2/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -164.4% | -6.4% | +15.9% | +10.1% | +1.3% |
| ROA (TTM)Return on assets | -80.8% | -5.0% | +1.3% | +0.9% | +1.0% |
| ROICReturn on invested capital | -76.4% | +3.6% | +4.5% | +3.5% | +1.4% |
| ROCEReturn on capital employed | -80.4% | +4.5% | +8.9% | +4.5% | +1.5% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 3 | 5 | 7 | 4 |
| Debt / EquityFinancial leverage | 0.86x | 0.07x | 2.60x | 1.21x | 0.09x |
| Net DebtTotal debt minus cash | $12M | $23M | $599.0B | $134.1B | -$381M |
| Cash & Equiv.Liquid assets | $30M | $41M | $343.3B | $231.8B | $561M |
| Total DebtShort + long-term debt | $42M | $64M | $942.4B | $365.9B | $180M |
| Interest CoverageEBIT ÷ Interest expense | -32.73x | -5.99x | 0.74x | 0.48x | 6.16x |
Total Returns (Dividends Reinvested)
KTOS leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in KTOS five years ago would be worth $21,950 today (with dividends reinvested), compared to $515 for NYXH. Over the past 12 months, KTOS leads with a +40.0% total return vs NYXH's -81.6%. The 3-year compound annual growth rate (CAGR) favors KTOS at 59.1% vs NYXH's -44.0% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -69.1% | -33.4% | -0.5% | +1.1% | -27.2% |
| 1-Year ReturnPast 12 months | -81.6% | -10.3% | +21.8% | +28.1% | +40.0% |
| 3-Year ReturnCumulative with dividends | -82.4% | +76.1% | +138.2% | +103.0% | +302.4% |
| 5-Year ReturnCumulative with dividends | -94.9% | +50.6% | +118.2% | +47.1% | +119.5% |
| 10-Year ReturnCumulative with dividends | -94.2% | +445.9% | +465.8% | +368.2% | +1354.7% |
| CAGR (3Y)Annualised 3-year return | -44.0% | +20.8% | +33.6% | +26.6% | +59.1% |
Risk & Volatility
BAC leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
BAC is the less volatile stock with a 0.86 beta — it tends to amplify market swings less than KTOS's 2.18 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BAC currently trades 97.3% from its 52-week high vs NYXH's 16.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.10x | 1.90x | 0.94x | 0.86x | 2.18x |
| 52-Week HighHighest price in past year | $8.59 | $417.86 | $337.25 | $57.55 | $134.00 |
| 52-Week LowLowest price in past year | $1.26 | $156.29 | $262.71 | $43.66 | $39.00 |
| % of 52W HighCurrent price vs 52-week peak | +16.2% | +40.8% | +95.1% | +97.3% | +43.1% |
| RSI (14)Momentum oscillator 0–100 | 25.8 | 49.4 | 59.1 | 68.3 | 48.3 |
| Avg Volume (50D)Average daily shares traded | 189K | 1.1M | 7.0M | 31.7M | 4.2M |
Analyst Outlook
Evenly matched — JPM and BAC each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: NYXH as "Buy", AVAV as "Buy", JPM as "Buy", BAC as "Buy", KTOS as "Buy". Consensus price targets imply 331.7% upside for NYXH (target: $6) vs 5.9% for JPM (target: $340). For income investors, BAC offers the higher dividend yield at 2.26% vs JPM's 1.86%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $6.00 | $292.20 | $339.75 | $61.13 | $110.00 |
| # AnalystsCovering analysts | 5 | 28 | 61 | 54 | 24 |
| Dividend YieldAnnual dividend ÷ price | — | — | +1.9% | +2.3% | — |
| Dividend StreakConsecutive years of raises | — | — | 15 | 12 | — |
| Dividend / ShareAnnual DPS | — | — | $5.95 | $1.27 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +3.9% | +5.1% | 0.0% |
JPM leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). BAC leads in 2 (Valuation Metrics, Risk & Volatility). 1 tied.
NYXH vs AVAV vs JPM vs BAC vs KTOS: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is NYXH or AVAV or JPM or BAC or KTOS a better buy right now?
For growth investors, Nyxoah S.
A. (NYXH) is the stronger pick with 121. 6% revenue growth year-over-year, versus -0. 5% for Bank of America Corporation (BAC). Bank of America Corporation (BAC) offers the better valuation at 14. 7x trailing P/E (12. 6x forward), making it the more compelling value choice. Analysts rate Nyxoah S. A. (NYXH) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — NYXH or AVAV or JPM or BAC or KTOS?
On trailing P/E, Bank of America Corporation (BAC) is the cheapest at 14.
7x versus Kratos Defense & Security Solutions, Inc. at 444. 2x. On forward P/E, Bank of America Corporation is actually cheaper at 12. 6x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 0. 81x versus Bank of America Corporation's 0. 82x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — NYXH or AVAV or JPM or BAC or KTOS?
Over the past 5 years, Kratos Defense & Security Solutions, Inc.
(KTOS) delivered a total return of +119. 5%, compared to -94. 9% for Nyxoah S. A. (NYXH). Over 10 years, the gap is even starker: KTOS returned +1355% versus NYXH's -94. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — NYXH or AVAV or JPM or BAC or KTOS?
By beta (market sensitivity over 5 years), Bank of America Corporation (BAC) is the lower-risk stock at 0.
86β versus Kratos Defense & Security Solutions, Inc. 's 2. 18β — meaning KTOS is approximately 153% more volatile than BAC relative to the S&P 500. On balance sheet safety, AeroVironment, Inc. (AVAV) carries a lower debt/equity ratio of 7% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.
05Which is growing faster — NYXH or AVAV or JPM or BAC or KTOS?
By revenue growth (latest reported year), Nyxoah S.
A. (NYXH) is pulling ahead at 121. 6% versus -0. 5% for Bank of America Corporation (BAC). On earnings-per-share growth, the picture is similar: Bank of America Corporation grew EPS 18. 6% year-over-year, compared to -30. 9% for Nyxoah S. A.. Over a 3-year CAGR, NYXH leads at 48. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — NYXH or AVAV or JPM or BAC or KTOS?
JPMorgan Chase & Co.
(JPM) is the more profitable company, earning 20. 4% net margin versus -899. 1% for Nyxoah S. A. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -827. 8% for NYXH. At the gross margin level — before operating expenses — NYXH leads at 63. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is NYXH or AVAV or JPM or BAC or KTOS more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 0. 81x versus Bank of America Corporation's 0. 82x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Bank of America Corporation (BAC) trades at 12. 6x forward P/E versus 75. 9x for Kratos Defense & Security Solutions, Inc. — 63. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NYXH: 331. 7% to $6. 00.
08Which pays a better dividend — NYXH or AVAV or JPM or BAC or KTOS?
In this comparison, BAC (2.
3% yield), JPM (1. 9% yield) pay a dividend. NYXH, AVAV, KTOS do not pay a meaningful dividend and should not be held primarily for income.
09Is NYXH or AVAV or JPM or BAC or KTOS better for a retirement portfolio?
For long-horizon retirement investors, Bank of America Corporation (BAC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
86), 2. 3% yield, +368. 2% 10Y return). Nyxoah S. A. (NYXH) carries a higher beta of 2. 10 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BAC: +368. 2%, NYXH: -94. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between NYXH and AVAV and JPM and BAC and KTOS?
These companies operate in different sectors (NYXH (Healthcare) and AVAV (Industrials) and JPM (Financial Services) and BAC (Financial Services) and KTOS (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: NYXH is a small-cap high-growth stock; AVAV is a small-cap quality compounder stock; JPM is a large-cap deep-value stock; BAC is a large-cap deep-value stock; KTOS is a mid-cap high-growth stock. JPM, BAC pay a dividend while NYXH, AVAV, KTOS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.